MRI-targeted ultrasound transperineal prostate biopsy can increase the detection rate and treatment of prostatic carcinoma compared to conventional prostate biopsy.

 

Prostate cancer is the most prevalent form of cancer in men over the age of 65.

 

One in every six males will acquire prostatic cancer, according to statistics.

 

In the previous decades, prostate cancer was commonly detected in the metastatic phase due to luck of specific symptoms during the early phase of the disease. PSA had considerably improved the early identification of prostate cancer. The only accurate procedure for identifying prostate cancer is a prostate biopsy.

 

The most frequently used biopsy was Transrectal Ultrasound Guided Biopsy (TRUS biopsy). Result of these biopsy is occasionally healthy tissue, because prostatic cancer is not visible ultrasound, which was used only to make a uniform biopsy of the gland. Passing the colon could have significant inflammatory consequences.

 

Despite multiple disadvantages, TRUS biopsy is still in use un many low currency areas.

 

Modern Magnetic Resonance Imaging (MRI) devices and the widespread use of multiparametric MRI make it easier to spot worrisome areas of the prostate. This type of examination could only be conducted by an expert radiologist in close collaboration with a urologist.

 

Transperineal systemic and MRI targeted prostate biopsies are offered and practiced at our clinic.

 

Using MRI result as a guide, the most suspicious prostate tissue samples are obtained. Utilizing a sterile surgical field prevents inflammatory problems.

Using this approach, life threatening prostatic cancer is better discovered.

 

The last but probably the most important is that pathohistological findings are interpreted by the single specialist of uropathology for more than two decades.

 

ONLY TRANSPERINEAL MRI-TARGETED PROSTATE BIOPSY IS RECOMMENDED BY THE EUROPEAN ASSOCIATION of UROLOGY (www.uroweb.org 2023).